Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses

Mike C. Jentsch, Erin M. Van Buel, Fokko J. Bosker*, Anatoliy Gladkevich, Hans C. Klein, Richard Oude Voshaar, Eric G. Ruhe, Uli L. M. Eisel, Robert A. Schoevers

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

38 Citations (Scopus)

Abstract

Major depressive disorder is a heterogeneous disorder, mostly diagnosed on the basis of symptomatic criteria alone. It would be of great help when specific biomarkers for various subtypes and symptom clusters of depression become available to assist in diagnosis and subtyping of depression, and to enable monitoring and prognosis of treatment response. However, currently known biomarkers do not reach sufficient sensitivity and specificity, and often the relation to underlying pathophysiology is unclear. In this review, we evaluate various biomarker approaches in terms of scientific merit and clinical applicability. Finally, we discuss how combined biomarker approaches in both preclinical and clinical studies can help to make the connection between the clinical manifestations of depression and the underlying pathophysiology.

Original languageEnglish
Pages (from-to)277-297
Number of pages21
JournalBiomarkers in medicine
Volume9
Issue number3
DOIs
Publication statusPublished - 2015

Keywords

  • biomarkers
  • clinical research
  • genomics
  • major depressive disorder
  • neuro-imaging
  • preclinical research
  • proteomics
  • SEROTONIN TRANSPORTER BINDING
  • POSITRON-EMISSION-TOMOGRAPHY
  • ENDOTHELIAL GROWTH-FACTOR
  • MESSENGER-RNA EXPRESSION
  • GENE-ENVIRONMENT INTERACTIONS
  • ANTERIOR CINGULATE CORTEX
  • NEUROTROPHIC FACTOR
  • MOOD DISORDERS
  • MONOAMINE-OXIDASE
  • BIPOLAR DISORDER

Cite this